Radical Cystectomy vs. Multimodality Treatment in T2N0M0 Bladder Cancer : A Population-based, Age-matched Analysis
Copyright © 2021 Elsevier Ltd. All rights reserved..
BACKGROUND: Controversy still exists regarding efficacy of multimodality treatment (MMT) vs. radical cystectomy (RC) for urothelial carcinoma of the urinary bladder (UCUB).
METHODS: Within the SEER database (2004-2016), we retrospectively identified patients with stage T2N0M0 UCUB. Competing risks regression (CRR) tested cancer-specific mortality (CSM) and adjusted for other-cause mortality after MMT vs. RC. Exact matching for age was applied. Subgroup analyses focused on differences in chemotherapy or lymph node dissection rates. In sensitivity analyses, we accounted for 40% understaging rate in patients who underwent MMT.
RESULTS: Of 9862 patients with T2N0M0 UCUB, 2675 (27.1%) underwent MMT vs. 5751 (58.3%) RC vs. 1436 (14.6%) radiotherapy (RT) without chemotherapy. MMT rate increased (annually +3.0%, P < .01) and MMT patient age was significantly higher (median 77 years) than RC patient age (68 years). In exact age-matched analyses, 10-year CSM rates were 44.3% vs. 25.9% for MMT vs. RC (multivariate hazard ratio [HR] 0.48); 44.1% vs. 22.8% for MMT vs. RC with chemotherapy (HR 0.43); 40.5% vs. 31.1% for MMT vs. RC without lymph node dissection (HR 0.66), and 55.6% vs. 27.3% for RT without chemotherapy vs. RC (HR 0.37, all P < .001). Sensitivity analyses that addressed understaging of patients who underwent MMT resulted in virtually the same CSM rates.
CONCLUSION: In patents with T2N0M0, MMT or even more so RT alone may be associated with higher CSM than RC, even in exact age-matched multivariate CRR analyses, which adjust for other-cause mortality. In consequence, patients with T2 UCUB should be informed of this possible CSM disadvantage outside of highly specialized centers.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:19 |
|---|---|
| Enthalten in: |
Clinical genitourinary cancer - 19(2021), 4 vom: 07. Aug., Seite e264-e271 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Deuker, Marina [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Exact matching |
|---|
| Anmerkungen: |
Date Completed 10.09.2021 Date Revised 10.09.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.clgc.2021.03.010 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM32523793X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM32523793X | ||
| 003 | DE-627 | ||
| 005 | 20231225192023.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.clgc.2021.03.010 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1084.xml |
| 035 | |a (DE-627)NLM32523793X | ||
| 035 | |a (NLM)33972185 | ||
| 035 | |a (PII)S1558-7673(21)00073-2 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Deuker, Marina |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Radical Cystectomy vs. Multimodality Treatment in T2N0M0 Bladder Cancer |b A Population-based, Age-matched Analysis |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 10.09.2021 | ||
| 500 | |a Date Revised 10.09.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2021 Elsevier Ltd. All rights reserved. | ||
| 520 | |a BACKGROUND: Controversy still exists regarding efficacy of multimodality treatment (MMT) vs. radical cystectomy (RC) for urothelial carcinoma of the urinary bladder (UCUB) | ||
| 520 | |a METHODS: Within the SEER database (2004-2016), we retrospectively identified patients with stage T2N0M0 UCUB. Competing risks regression (CRR) tested cancer-specific mortality (CSM) and adjusted for other-cause mortality after MMT vs. RC. Exact matching for age was applied. Subgroup analyses focused on differences in chemotherapy or lymph node dissection rates. In sensitivity analyses, we accounted for 40% understaging rate in patients who underwent MMT | ||
| 520 | |a RESULTS: Of 9862 patients with T2N0M0 UCUB, 2675 (27.1%) underwent MMT vs. 5751 (58.3%) RC vs. 1436 (14.6%) radiotherapy (RT) without chemotherapy. MMT rate increased (annually +3.0%, P < .01) and MMT patient age was significantly higher (median 77 years) than RC patient age (68 years). In exact age-matched analyses, 10-year CSM rates were 44.3% vs. 25.9% for MMT vs. RC (multivariate hazard ratio [HR] 0.48); 44.1% vs. 22.8% for MMT vs. RC with chemotherapy (HR 0.43); 40.5% vs. 31.1% for MMT vs. RC without lymph node dissection (HR 0.66), and 55.6% vs. 27.3% for RT without chemotherapy vs. RC (HR 0.37, all P < .001). Sensitivity analyses that addressed understaging of patients who underwent MMT resulted in virtually the same CSM rates | ||
| 520 | |a CONCLUSION: In patents with T2N0M0, MMT or even more so RT alone may be associated with higher CSM than RC, even in exact age-matched multivariate CRR analyses, which adjust for other-cause mortality. In consequence, patients with T2 UCUB should be informed of this possible CSM disadvantage outside of highly specialized centers | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Exact matching | |
| 650 | 4 | |a Radiation | |
| 650 | 4 | |a Surgery | |
| 650 | 4 | |a Survival | |
| 650 | 4 | |a Trimodal therapy | |
| 700 | 1 | |a Krimphove, Marieke J |e verfasserin |4 aut | |
| 700 | 1 | |a Stolzenbach, L Franziska |e verfasserin |4 aut | |
| 700 | 1 | |a Collà Ruvolo, Claudia |e verfasserin |4 aut | |
| 700 | 1 | |a Nocera, Luigi |e verfasserin |4 aut | |
| 700 | 1 | |a Mansour, Mila |e verfasserin |4 aut | |
| 700 | 1 | |a Tian, Zhe |e verfasserin |4 aut | |
| 700 | 1 | |a Roos, Frederik C |e verfasserin |4 aut | |
| 700 | 1 | |a Becker, Andreas |e verfasserin |4 aut | |
| 700 | 1 | |a Kluth, Luis A |e verfasserin |4 aut | |
| 700 | 1 | |a Shariat, Shahrokh F |e verfasserin |4 aut | |
| 700 | 1 | |a Black, Peter C |e verfasserin |4 aut | |
| 700 | 1 | |a Kassouf, Wassim |e verfasserin |4 aut | |
| 700 | 1 | |a Tilki, Derya |e verfasserin |4 aut | |
| 700 | 1 | |a Saad, Fred |e verfasserin |4 aut | |
| 700 | 1 | |a Chun, Felix K H |e verfasserin |4 aut | |
| 700 | 1 | |a Karakiewicz, Pierre I |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical genitourinary cancer |d 2005 |g 19(2021), 4 vom: 07. Aug., Seite e264-e271 |w (DE-627)NLM160229936 |x 1938-0682 |7 nnns |
| 773 | 1 | 8 | |g volume:19 |g year:2021 |g number:4 |g day:07 |g month:08 |g pages:e264-e271 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.clgc.2021.03.010 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 19 |j 2021 |e 4 |b 07 |c 08 |h e264-e271 | ||